Open AccessNovel Patented Markers of Immune Checkpoint Inhibitor Efficacy
Author(s) -
Matthieu Collin
Publication year - 2018
Publication title -
pharmaceutical patent analyst
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.247
H-Index - 15
eISSN - 2046-8962
pISSN - 2046-8954
DOI - 10.4155/ppa-2018-0005
Subject(s) - nivolumab , pembrolizumab , durvalumab , immune checkpoint , atezolizumab , avelumab , cancer research , tumor microenvironment , immune system , btla , antibody , tigit , monoclonal antibody , immunotherapy , immunology , biology , t cell
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom